Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant

References

• Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma— a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149–157.
   PubMed Web of Science ®Google Scholar
• McMillan A, Ardeshna KM, Cwynarski K, et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol 2013;163: 168–181.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011;29: 1452–1457.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Magagnoli M, Frezza G, et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999;32:571–576.
   PubMed Web of Science ®Google Scholar
• Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013;98:364–370.
   PubMed Web of Science ®Google Scholar
• Chen YB, Batchelor T, Li S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 2015;121:226–233.
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:352–358.
   PubMed Web of Science ®Google Scholar
• Bromberg JE, Doorduijn JK, Illerhaus G, et al. Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation—an International Primary Central Nervous System Lymphoma Study Group project. Haematologica 2013;98:808–813.
   PubMed Web of Science ®Google Scholar
• Jahnke K, Thiel E, Martus P, et al. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 2006;85:45–50.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Jones RJ, Piantadosi S, et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 2005;11:93–100.
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Wang Z, Zhang MJ, et al. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. Br J Haematol 2013;162:648–656.
   PubMed Web of Science ®Google Scholar
• Khan RB, Shi W, Thaler HT, et al. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 2002;58:175–178.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013;31: 3061–3068.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Alimohamed N, Daly A, Owen C, et al. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk Lymphoma 2012;53:862–867.
   PubMed Web of Science ®Google Scholar
• Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003;31:679–685.
   PubMed Web of Science ®Google Scholar
• Schiffman K, Buckner CD, Maziarz R, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997;3:261–266.
   PubMedGoogle Scholar
• Bains T, Chen AI, Lemieux A, et al. Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma 2014;55:583–587.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Delgado F, Holmberg L, Hooper H, et al. Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003;32:279–285.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• Zaucha R, Gooley T, Holmberg L, et al. High-dose chemotherapy with BEAM or busulphan/melphalan and thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008;49:1899–1906.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151–4156.
   PubMed Web of Science ®Google Scholar
• Williams CD, Pearce R, Taghipour G, et al. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome—a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 1994;12:2415–2422.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007;18:1085–1089.
   PubMed Web of Science ®Google Scholar
• Bollen EL, Brouwer RE, Hamers S, et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997;54:854–859.
   PubMed Web of Science ®Google Scholar
• Abramson JS. High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen. Haematologica 2013;98:662–664.
   PubMed Web of Science ®Google Scholar
• Oh DH, Ghosh S, Chua N, et al. Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis. Leuk Lymphoma 2014 Nov 3. [E-pub ahead of print]
   Web of Science ®Google Scholar
• Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989;49:736–741.
   PubMed Web of Science ®Google Scholar
• Hassan M, Ehrsson H, Smedmyr B, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 1989;4:113–114.
   PubMed Web of Science ®Google Scholar
• Wiebe VJ, Smith BR, DeGregorio MW, et al. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992;13:241–270.
   PubMed Web of Science ®Google Scholar
• Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989;11:74–86.
   PubMedGoogle Scholar
• Hande KR, Wedlund PJ, Noone RM, et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 1984;44:379–382.
   PubMed Web of Science ®Google Scholar
• Postmus PE, Holthuis JJ, Haaxma-Reiche H, et al. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 1984;2:215–220.
   PubMed Web of Science ®Google Scholar
• Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012;18:76–83.
   PubMed Web of Science ®Google Scholar
• Welch MR, Sauter CS, Matasar MJ, et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leuk Lymphoma 2015;56:361–367.
   PubMed Web of Science ®Google Scholar